Catalent Executive and Leadership Team

Matti Masanovich, the Senior Vice President & Chief Financial Officer at Catalent, directs the global financial strategy and capital allocation processes. Overseeing fiscal planning, the Senior Vice President & Chief Financial Officer ensures that investment in development sciences and manufacturing infrastructure remains robust. This leadership role involves managing investor relations and maintaining financial transparency across all business segments. By optimizing the cost structure, Matti Masanovich directly impacts the company's operational efficiency and profitability. Ultimately, Masanovich secures the financial foundation necessary for long-term innovation. The Senior Vice President & Chief Financial Officer evaluates capital expenditure projects to support the expansion of multi-modality manufacturing capabilities. By driving financial discipline, the Senior Vice President & Chief Financial Officer enables the company to navigate complex market dynamics. Masanovich collaborates with the executive team to align financial resources with the strategic goal of accelerating drug development for global partners.

Christopher Hajjar, the Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer at Catalent, directs financial operations specifically for the biologics segment. Overseeing segment-specific budgeting, the Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer ensures that resource allocation supports the rapid development of personalized medicines. This leadership role involves analyzing financial performance to drive profitability in complex manufacturing environments. By optimizing the financial planning process, Christopher Hajjar directly impacts the company's ability to scale biologics production. Ultimately, Hajjar secures the financial viability of high-growth therapeutic projects. The Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer monitors cost-efficiency in the biologics supply chain. By driving financial insights, the Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer supports strategic decision-making. Hajjar collaborates with operational leaders to ensure that financial targets align with the technical requirements of biologics manufacturing.

Aris Gennadios, the Group President, Pharma & Consumer Health at Catalent, directs the operational strategy for the pharmaceutical and consumer health business units. Overseeing the manufacturing and development lifecycle, the Group President, Pharma & Consumer Health ensures that product delivery meets the highest quality standards for global partners. This leadership role involves managing large-scale production facilities and driving technological advancements in drug delivery. By optimizing manufacturing workflows, Aris Gennadios directly impacts the company's ability to bring products to market efficiently. Ultimately, Gennadios secures the company's reputation as a leader in CDMO services. The Group President, Pharma & Consumer Health coordinates with regional leaders to ensure consistent operational performance across international markets. By driving innovation in consumer health brand extensions, the Group President, Pharma & Consumer Health expands the company's market footprint. Gennadios collaborates with the executive team to align operational capacity with the evolving needs of the global pharmaceutical industry.

Sarah Hauer, the Chief Revenue Officer at Catalent, directs all global commercial strategies to expand market reach for pharmaceutical and biotech partners. Overseeing the integration of development services with client needs, the Chief Revenue Officer ensures alignment with corporate growth targets. This leadership role involves scaling revenue streams across diverse therapeutic modalities. By optimizing the commercial pipeline, Sarah Hauer directly impacts the company's ability to support blockbuster drug launches. Ultimately, Hauer secures long-term financial stability through strategic partnerships. The Chief Revenue Officer manages complex contract negotiations, ensuring that service offerings meet the evolving demands of the global healthcare market. By driving North American and international sales initiatives, the Chief Revenue Officer maintains a competitive edge in the CDMO sector. Hauer fosters deep collaboration with internal development teams to ensure that revenue goals remain synchronized with manufacturing capacity and technological capabilities.

Kassandra Walsh, the Senior Account Director & Chief Revenue Officer at Catalent, manages high-value client relationships to drive sustainable revenue growth. Overseeing the account management framework, the Senior Account Director & Chief Revenue Officer ensures that consumer health brand extensions receive dedicated support. This leadership role involves translating complex manufacturing requirements into actionable commercial strategies. By refining the client engagement model, Kassandra Walsh directly impacts the company's market penetration in the consumer health segment. Ultimately, Walsh secures long-term loyalty through consistent service delivery. The Senior Account Director & Chief Revenue Officer coordinates with cross-functional teams to align account objectives with global supply chain capabilities. By driving regional market expansion, the Senior Account Director & Chief Revenue Officer strengthens the company's position as a preferred partner. Walsh monitors performance metrics to ensure that account-specific revenue targets support the broader organizational mission of improving patient health outcomes.

Lisa Evoli, the Senior Vice President and Chief Human Resources Officer at Catalent, directs the global talent strategy and organizational development initiatives. Overseeing workforce planning, the Senior Vice President and Chief Human Resources Officer ensures that the company attracts and retains top-tier expertise in pharmaceutical manufacturing. This leadership role involves fostering a culture of innovation and operational excellence across all global sites. By optimizing human capital programs, Lisa Evoli directly impacts the company's ability to execute complex development projects. Ultimately, Evoli secures the organizational health required for sustained growth. The Senior Vice President and Chief Human Resources Officer manages leadership development and diversity initiatives to support a high-performing workforce. By driving employee engagement, the Senior Vice President and Chief Human Resources Officer aligns individual performance with the company's mission. Evoli collaborates with the executive team to ensure that talent strategies support the scaling of manufacturing and delivery technologies.